Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.
Company profile
Ticker
MRK, MRK-FP, MRK-PE, MRK-MM
Exchange
Website
CEO
Kenneth Frazier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Merck & Co. Inc., SCHERING PLOUGH CORP
SEC CIK
Corporate docs
Subsidiaries
7728026 Canada Inc. • Abmaxis Inc. • Acceleron Pharma Inc. • Afferent Pharmaceuticals, Inc. • Agrident GmbH • Agro Verhen B.V. • Allflex Argentina S.A. • Allflex Australia • Allflex (China) Intelligent Technology Co. Ltd. • Allflex dan-mark ApS ...
IRS number
221918501
MRK stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
20 May 24
FWP
Free writing prospectus
16 May 24
424B5
Prospectus supplement for primary offering
15 May 24
POSASR
Automatic shelf registration (post-effective amendment)
15 May 24
10-Q
2024 Q1
Quarterly report
3 May 24
8-K
Merck Announces First-Quarter 2024 Financial Results
25 Apr 24
ARS
2023 FY
Annual report to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
10-K/A
2023 FY
Annual report (amended)
11 Apr 24
Transcripts
MRK
Earnings call transcript
2024 Q1
25 Apr 24
MRK
Earnings call transcript
2023 Q4
1 Feb 24
MRK
Earnings call transcript
2023 Q3
26 Oct 23
MRK
Earnings call transcript
2023 Q2
1 Aug 23
MRK
Earnings call transcript
2023 Q2
1 Aug 23
MRK
Earnings call transcript
2023 Q1
27 Apr 23
MRK
Earnings call transcript
2022 Q4
2 Feb 23
MRK
Earnings call transcript
2022 Q3
27 Oct 22
MRK
Earnings call transcript
2022 Q2
28 Jul 22
MRK
Earnings call transcript
2022 Q1
28 Apr 22
Latest ownership filings
144
Notice of proposed sale of securities
6 May 24
4
Dalton Smart
6 May 24
4
Richard R. DeLuca
6 May 24
4
Michael A Klobuchar
6 May 24
4
Johannes Jacobus Oosthuizen
6 May 24
4
Joseph Romanelli
2 May 24
4
Betty D Larson
2 May 24
4
Dalton Smart
2 May 24
4
Chirfi Guindo
2 May 24
4
Cristal N Downing
2 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.67 bn | 5.67 bn | 5.67 bn | 5.67 bn | 5.67 bn | 5.67 bn |
Cash burn (monthly) | 412.67 mm | 342.92 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 681.27 mm | 566.12 mm | n/a | n/a | n/a | n/a |
Cash remaining | 4.99 bn | 5.10 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | 12.1 | 14.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
52.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2851 |
Opened positions | 295 |
Closed positions | 506 |
Increased positions | 1040 |
Reduced positions | 1234 |
13F shares | Current |
---|---|
Total value | 134.99 tn |
Total shares | 1.33 bn |
Total puts | 4.75 mm |
Total calls | 2.87 mm |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 244.78 mm | $26.69 tn |
STT State Street | 116.87 mm | $12.83 tn |
Wellington Management | 85.60 mm | $9.33 tn |
FMR | 42.80 mm | $4.67 tn |
MS Morgan Stanley | 40.13 mm | $4.37 tn |
Charles Schwab Investment Management | 36.68 mm | $3.97 tn |
T. Rowe Price | 30.09 mm | $3.28 bn |
NTRS Northern Trust | 28.49 mm | $3.11 tn |
JPM JPMorgan Chase & Co. | 25.41 mm | $2.77 tn |
LGEN Legal & General | 23.49 mm | $2.56 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 May 24 | Johannes Jacobus Oosthuizen | Common Stock | Payment of exercise | Dispose F | No | No | 127.51 | 450 | 57.38 k | 23,820.949 |
4 May 24 | Johannes Jacobus Oosthuizen | Common Stock | Option exercise | Acquire M | No | No | 127.51 | 912 | 116.29 k | 24,270.949 |
4 May 24 | Johannes Jacobus Oosthuizen | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 912 | 0.00 | 0 |
4 May 24 | Michael A Klobuchar | Common Stock | Payment of exercise | Dispose F | No | No | 127.51 | 437 | 55.72 k | 23,621.195 |
4 May 24 | Michael A Klobuchar | Common Stock | Option exercise | Acquire M | No | No | 127.51 | 887 | 113.10 k | 24,058.195 |
4 May 24 | Michael A Klobuchar | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 887 | 0.00 | 0 |
4 May 24 | Richard R. DeLuca | Common Stock | Payment of exercise | Dispose F | No | No | 127.51 | 13,360 | 1.70 mm | 150,359.559 |
4 May 24 | Richard R. DeLuca | Common Stock | Option exercise | Acquire M | No | No | 127.51 | 27,126 | 3.46 mm | 163,719.559 |
4 May 24 | Richard R. DeLuca | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 27,126 | 0.00 | 0 |
4 May 24 | Dalton Smart | Common Stock | Payment of exercise | Dispose F | No | No | 127.51 | 302 | 38.51 k | 4,428.286 |
News
10 Health Care Stocks Whale Activity In Today's Session
17 May 24
Check Out What Whales Are Doing With MRK
16 May 24
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
16 May 24
10 Health Care Stocks With Whale Alerts In Today's Session
15 May 24
Merck Ends Keytruda Combo Melanoma Study Due to Futility
14 May 24
Press releases
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
15 May 24
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
13 May 24
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
9 May 24
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
9 May 24
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
8 May 24